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Introduction
Anti-inflammatory treatment of childhood asthma" cromoglycate
and nedocromil as non-steroidal alternatives?
Since asthma has been recognized as a chronic in-
flammator disorder of the airways, anti-inflamma-
tory drugs and, in particular, corticosteroids have
become first-line treatment. 1,2 Concern remains on
the potential side-effects of inhaled corticosteroids
especially in children. Inhaled steroids have an ex-
cellent safety profile, and are widely used in paedi-
atric asthma treatment. Their long-term use in young
children is generally thought to be both safe and
effective, but small systemic effects can be demon-
strated even with moderate doses. 5,6 These effects
include the short-term inhibition of growth of long
bones, and the suppression of basal cortisol secre-
tion levels. Apart from these, there are risks of local
side-effects including hoarseness and thrush. It is,
however, generally felt that the benefits of steroids in
asthmatic children greatly outweigh the small poten-
tial risks.
Despite the low toxicity of inhaled steroids, the
availability of non-steroidal anti-inflammatory medi-
cation for treating asthmatic children is highly desir-
able because of the relatively high numbers of asth-
matic children requiring maintenance treatment, and
the long duration of anti-inflammatory asthma treat-
ment. Two effective non-steroidal anti-asthma drugs
with anti-inflammatory activities are presently avail-
able: cromoglycate and nedocromil. Of these
cromoglycate has been used for many years and has
proven to be both effective and extremely safe.
Cromoglycate has been advocated as a first-choice
drug for moderate paediatric asthma where mainte-
nance treatment is required. Much less data are
available on nedocromil, a novel pyranoquinoline
dicarboxylic acid with a broad "spectrum of anti-
inflammatory actions. Nedocromil is more potent
than cromoglycate, but it has been difficult to prove
its superiority to cromoglycate in vivo. Data on the
effect of nedocromil in children with asthma are
scanty, and tend to confirm its effectiveness in mod-
erate asthma. The data presently available do not
permit a clear positioning of the drug in clinical
paediatric practice. Because nedocromil is one of the
few drugs without steroid side-effects which can be
applied in childhood asthma, and because it has anti-
inflammatory effects, it deserves thorough study.
The present supplement issue of Mediators ofIn-
flammatio contains a selection of papers and ab-
stracts on cromoglycate and nedocromil in childhood
asthma from a recent symposium, where both clinical
and laboratory studies on nedocromil were reported
in order to get a better understanding of their mecha-
nisms of action, especially in children. The editors
think that publishing these original data may help in
the further positioning of these drugs in the treat-
ment of childhood asthma, an important and increas-
ing disease with a major impact on childhood health.
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